South Africa has become the first African country to register lenacapavir, a groundbreaking six-monthly HIV prevention ...
The South African Health Products Regulatory Authority (SAHPRA) has announced the registration of lenacapavir, making South ...
Roche Holdings AG's (OTC:RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with ...
LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial ...
– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces multiple poster presentations of its obesity assets including ASC30, and combination of ASC31 and ASC47 at ObesityWeek® 2025 in Atlanta, Georgia ...
1. About lecanemab (generic name, brand name: LEQEMBI®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal ...
Key points A 40-year-old woman presented to her family physician with a new subcutaneous mass in the right lower quadrant of her abdomen, along with nonspecific systemic symptoms, including occasional ...
Credit: Getty Images. The resubmitted NDA was in response to a Complete Response Letter issued by the FDA in December 2021. The Food and Drug Administration (FDA) has accepted the resubmitted New Drug ...
PharmaJet will deliver 2 presentations at the PODD conference on Oct. 27 focusing on current and future applications of their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback